Could a transplant drug boost brain cancer treatment?
NCT ID NCT05236036
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests adding mycophenolate mofetil, a drug usually used to prevent organ rejection, to standard chemotherapy and radiation for glioblastoma. The goal is to find a safe dose and see if the combination can make tumor cells more sensitive to treatment. About 60 adults with newly diagnosed or recurrent glioblastoma are taking part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTROCYTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Northwestern Lake Forest Hospital
Lake Forest, Illinois, 60045, United States
-
Northwestern Medicine Warrenville
Warrenville, Illinois, 60555, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New imaging clues could sharpen brain tumor monitoring
- Can a virus injected into brain tumors fight recurrence?
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can a seizure drug outsmart a deadly brain tumor?
- A simple lotion duo may shield skin from Tumor-Treating fields
- Can a One-Two punch slow recurrent brain cancer?